From above, a new landmark in regenerative medicine is taking shape in the China (Shanghai) Pilot Free Trade Zone—the Regend Therapeutics Stem Cell Drug Manufacturing Base.

Inside the facility, two world-class cell manufacturing lines are ready for operation: one dedicated to regenerative therapies for lung diseases, the other focused on kidney regeneration. Together, they represent a major step forward in advancing regenerative medicine from scientific innovation to large-scale clinical manufacturing.

With full-scale production targeted for the first half of next year, the facility is preparing to support the delivery of high-quality stem cell therapies to patients and accelerate the clinical translation of regenerative medicine.

The future of regenerative medicine is taking shape today. Follow Regend Therapeutics' official video channel and join us as we mark this exciting milestone.